Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00812240 · ClinicalTrials.gov registry record · Phase 3
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
A Phase 3 study, sponsored by AB Science.
- Terminated
- Registry status
- Phase 3
- Development phase
- 335
- Enrollment target
NCT00812240: Clinical Trial Phase 3 study, sponsored by AB Science.
NCT00812240 is a Phase 3 study that was terminated before completion, run by AB Science. The registered enrollment target is 335 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00812240, a Phase 3 study, was terminated before completion, sponsored by AB Science.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 335 participants
- Enrollment target
Study Summary
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
Primary Outcome
Progression Free Survival is defined as the time from randomization to first documentation of objective tumor progression (date of tumor assessment documenting progressive disease assessed by CT Scan according to RECIST 1.1 and based on central review) or to death due to any cause (whichever comes first).
Interventions
- DRUG Imatinib
- DRUG Masitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2009-01 |
| Est. Completion | 2018-07 |
| Phase | Phase 3 |
Why NCT00812240 stopped before completion
NCT00812240 is an interventional study that assigns participants to a tested intervention. The registered 335 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which Imatinib is the first listed.
NCT00812240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00812240 about?
NCT00812240 is a clinical study titled "Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)". Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
What is the current status of trial NCT00812240?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 335 participants. The study started on 2009-01. Estimated completion is 2018-07.
What interventions are being tested in trial NCT00812240?
The interventions under investigation include: Imatinib (DRUG), Masitinib (DRUG).
Who is sponsoring clinical trial NCT00812240?
This trial is sponsored by AB Science, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00812240's enrollment target sits among peer trials
335 1061st of 2000 higher than 940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134754 · 335 participants · NA
Carbon Dioxide (CO2) Chemosensitivity and SUDEP
- NCT05554406 · 335 participants · Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT06183437 · 335 participants · Phase 4
The STOP-MED CTRCD Trial
- NCT06885177 · 335 participants · NA
TECTONIC CAD IVL IDE Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia